one positive note about shorts is that they lower the price low enough where longs can buy more... That's just sweet cooperation and team work on their part. hope you loaded up at 8.5 as it will knocking on $10 next week...
the competition which is only 2 products are by weekly iv medications,,,,,that also comes with a 200k yearly fee,,,,(,plus folds pipeline),,,,would u rather get stuck with a needle and wait for a iv bag to drain at the hospital every 2 weeks or take a pill once a day'''''
Sentiment: Strong Buy
You messed up the computation - the previous post notes the JPM estimate of $350M-$400M worldwide potential for Galafold with 70% ex-US - that translates to $245M-$280M outside the US. The $350M-$400M already accounts for the amenable mutation allocation - the entire Fabry ERT market is currently $1B+. Crowley has talked about how Fabry is under-diagnosed and under-treated, as many patients avoid the ERT infusions until their disease progresses, so Galafold may be able to capture a larger population than is currently represented by the ERT patients.
I have never seen a significant pop from a biotech upon European approval - most biotech investors think until you have US approval, it is not worth touching. For a lot of drugs and indications that is probably true, but the EU is more progressive and accepting of drug prices for rare diseases, particularly ones that are "personalized" (e.g. linked to a genetic test) and can improve the patient's quality of life. Whereas a lot of drugs have pricing in the EU that is half or less what can be charged in the US, I believe the pricing of drugs for rare diseases have more parity, which is why 70% of the potential $ market for Galafold is outside the US. Unfortunately, we will likely have to wait for meaningful revenues kick in before the "market" takes notice?
l.o.l good luck... 25 million shorts can be wrong and get hurt pretty bad on one more piece of good news.
you sound like a nervous short..
CHMP released it's highlights already!!! Galafold is recommended for marketing authorization!!!!! Go to their website and see it for yourself!! :) :) :) :)
I am so sick of this #$%$! Just with EU approval they have a potential $350 million per year revenue generator. They have the potential to reach $500 million after US approval, they have GREAT drugs in the pipeline, and they are only sitting at a $1 billion market cap. They lost 54% in ONE day after announcing they would not apply in the US right away but now they can't make a 5% gain the day of the approval announcement! Over 11 million shares traded hands between friday and today, when the heck are people going to stop selling this stock en mass? There is so much more money to be made!!
I'm new to FOLD, first shares on Friday and followed again on Monday. Looking forward to the fireworks.
Sentiment: Strong Buy
That's good despite the amount.
The sell for many reasons but they buy for just one...they think it's going higher.